Aberrant alternative splicing yields a secreted FGFR2 IIIa TM disease variant

Stable Identifier
Reaction [omitted]
Homo sapiens
Locations in the PathwayBrowser
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

A secreted truncated form of FGFR2 known as IIIa TM is produced and stable in a mouse model of Apert Syndrome. FGFR2 IIIa TM is formed from aberrant splicing of FGFR2 exon 7 (IIIa) into exon 10 (containing the transmembrane domain). In WT cells, this transcript is degraded by nonsense-mediated decay, but persists in the disease model by an unknown mechanism. FGFR IIIa TM modulates the binding of FGF1 to FGFR2 in vitro and negatively regulates FGFR2 signaling in vitro and in vivo (Wheldon et al, 2011).

Literature References
PubMed ID Title Journal Year
21355848 Identification and characterization of an inhibitory fibroblast growth factor receptor 2 (FGFR2) molecule, up-regulated in an Apert Syndrome mouse model

Wheldon, LM, Khodabukus, N, Patey, SJ, Smith, TG, Heath, JK, Hajihosseini, MK

Biochem. J. 2011
Participant Of
Inferred From
Name Identifier Synonyms
acrocephalosyndactylia 12960 Apert syndrome
Cite Us!